PF-02341066 (Crizotinib) is a potent, multi-target ATP-competitive ALK, MET, and ROS1 inhibitor. It blocks ALK/MET/ROS1 and downstream AKT/ERK/STAT3 signaling by binding to the kinase ATP-binding sites, effectively inhibiting tumor cell proliferation, migration, and inducing apoptosis.
PF-02341066 (Crizotinib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for PF-02341066 (Crizotinib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.
Jump to
- PF-02341066 (Crizotinib) Mechanism of Action: ALK Inhibition in Lung Adenocarcinoma Cell Research
- PF-02341066 (Crizotinib) Clinical Trials
- PF-02341066 (Crizotinib) Working Concentration | Cell Culture | Treatment
- PF-02341066 (Crizotinib) Solubility in DMSO
- PF-02341066 (Crizotinib) Stock Solution
- PF-02341066 (Crizotinib) Storage
- PF-02341066 (Crizotinib) Stability
- PF-02341066 (Crizotinib) Combination Database
- PF-02341066 (Crizotinib) Molecular Weight
- PF-02341066 (Crizotinib) SMILES
- PF-02341066 (Crizotinib) CAS Number
- PF-02341066 (Crizotinib) Chemical Structure (2D and 3D)
- PF-02341066 (Crizotinib) Sigma (PZ0191)? Try a better option.
- PF-02341066 (Crizotinib) MedChemExpress (HY-50878)? Try a better option.
- PF-02341066 (Crizotinib) Cayman (12087)? Try a better option.
- PF-02341066 (Crizotinib) APExBIO (A3020)? Try a better option.
- PF-02341066 (Crizotinib) SDS｜MSDS